Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro
Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro
复制标题
DOI:
10.1128/aac.49.11.4437-4442.2005
复制
发表时间:
2005-11-01
影响因子:
4.9
通讯作者:
Zhu, G
中科院分区:
文献类型:
--
作者:
Cai, XM;Woods, KM;Zhu, G
We report here on a quantitative real-time reverse transcription-PCR (qRT-PCR) assay for assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum. The qRT-PCR assay detects 18S rRNA transcripts from both parasites, that is, the cycle threshold for 18S rRNA from parasites (C,,P,,,,) and host cells (C-T[H18S]), and evaluates the relative expression between parasite and host rRNA levels (i.e., Delta C-T = C-T[P18S] - C-T[H18S]) to minimize experimental and operational errors. The choice of qRT-PCR over quantitative PCR (qPCR) in this study is based on the observations that (i) the relationship between the logarithm of infected parasites (log[PI) and the normalized relative level of rRNA (Delta Delta CT) is linear, with a fourfold dynamic range, by qRT-PCR but sigmoidal (nonlinear) by qPCR; and (ii) the level of RNA represents that of live parasites better than that of DNA, because the decay of RNA (99% in similar to 3 h) in dead parasites is faster than that of DNA (99% in similar to 24 to 48 h) under in vitro conditions. The reliability of the qRT-PCR method was validated by testing the efficacies of nitazoxanide and paromomycin on the development of two strains of C. parvum (IOWA and KSU-1) in HCT-8 cells in vitro. Both compounds displayed dose-dependent inhibitions. The observed MIC,, values for nitazoxanide and paromomycin were 0.30 to 0.45 mu g/ml and 89.7 to 119.0 mu g/ml, respectively, comparable to the values reported previously. Using the qRT-PCR assay, we have also observed that pyrazole could inhibit C. parvum development in vitro (MlC(50) = 15.8 mM), suggesting that the recently discovered Cryptosporidium alcohol dehydrogenases may be explored as new drug targets.